Login to Your Account

Cypress' Stock Plunges After Phase III Miss In Fibromyalgia

By Karen Pihl-Carey

Friday, September 30, 2005
Cypress Bioscience Inc. lost more than half its value Thursday after announcing that a pivotal Phase III study of milnacipran missed its primary endpoint as a treatment for pain associated with fibromyalgia. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription